Suppr超能文献

慢性疼痛患者接受丁丙诺啡治疗阿片类药物使用障碍时,对不适的不耐受、回避不适以及大麻和酒精使用之间的关联。

Associations of discomfort intolerance, discomfort avoidance, and cannabis and alcohol use among persons with chronic pain receiving prescription buprenorphine for opioid use disorder.

机构信息

Department of Community Health Sciences, Boston University School of Public Health, 801 Massachusetts Avenue, Boston, MA, USA.

Department of Health Law, Policy & Management, Boston University School of Public Health, Health, 715 Albany Street, Boston, MA 02118, USA; Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, 222 Richmond Street, Providence, RI 02903, USA.

出版信息

Drug Alcohol Depend. 2024 Dec 1;265:112472. doi: 10.1016/j.drugalcdep.2024.112472. Epub 2024 Oct 24.

Abstract

BACKGROUND

Chronic pain and non-prescribed substance use are associated with lower retention in opioid use disorder (OUD) treatment. We examined the associations of perceived capacity to tolerate uncomfortable physical sensations (discomfort intolerance and discomfort avoidance) and cannabis and alcohol use among persons with chronic pain receiving prescription buprenorphine for OUD.

METHODS

This study utilizes baseline data from 163 persons with chronic pain receiving prescription buprenorphine for OUD enrolled in the Treating Opioid use, Persistent Pain, and Sadness (TOPPS) intervention trial. We used negative-binomial regression models, adjusted for age, education, gender, race/ethnicity, pain interference, depression, generalized anxiety disorder, and average cigarettes smoked/day to estimate the associations of discomfort tolerance and discomfort avoidance with frequency of cannabis and alcohol use.

RESULTS

Participants (n=163) were on average 45 years old (standard deviation=10.6) and predominantly White (86 %, n=141). Forty-one percent (n=66) used cannabis and 24 % (n=30) used alcohol use in the past 30 days. In adjusted models, discomfort intolerance was positively associated with days of cannabis use (IRR = 1.11, p =.016) and days of alcohol use (IRR = 1.14, p =.022). Discomfort avoidance was not associated with cannabis or alcohol use.

CONCLUSION

Individuals with chronic pain receiving prescribed buprenorphine for treatment of OUD with lower tolerance for physical discomfort may augment pain management with cannabis and alcohol. Given the intersections between substance use and retention in care for OUD, future work should extend this preliminary work by exploring these relationships over time and in experimental settings. Clinical Trial # NCT03698669.

摘要

背景

慢性疼痛和非处方物质使用与阿片类药物使用障碍(OUD)治疗的保留率较低有关。我们研究了患有慢性疼痛并接受处方丁丙诺啡治疗 OUD 的患者中,感知忍受身体不适感觉的能力(不适耐受力和不适回避)与大麻和酒精使用之间的关联。

方法

本研究利用了接受处方丁丙诺啡治疗 OUD 的 163 名患有慢性疼痛患者的基线数据,这些患者参加了治疗阿片类药物使用、持续性疼痛和悲伤(TOPPS)干预试验。我们使用负二项回归模型,调整了年龄、教育程度、性别、种族/民族、疼痛干扰、抑郁、广泛性焦虑症和平均每天吸烟量,以估计不适耐受力和不适回避与大麻和酒精使用频率的关联。

结果

参与者(n=163)的平均年龄为 45 岁(标准差=10.6),主要为白人(86%,n=141)。41%(n=66)在过去 30 天内使用大麻,24%(n=30)使用酒精。在调整后的模型中,不适耐受力与大麻使用天数呈正相关(IRR=1.11,p=.016),与酒精使用天数呈正相关(IRR=1.14,p=.022)。不适回避与大麻或酒精使用无关。

结论

接受处方丁丙诺啡治疗 OUD 的慢性疼痛患者,如果对身体不适的耐受力较低,可能会通过使用大麻和酒精来增强疼痛管理。鉴于物质使用与 OUD 治疗保留率之间的交集,未来的工作应该通过在时间和实验环境中探索这些关系来扩展这项初步工作。临床试验#NCT03698669。

相似文献

10
Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.
Drug Alcohol Depend. 2021 Apr 1;221:108619. doi: 10.1016/j.drugalcdep.2021.108619. Epub 2021 Feb 15.

本文引用的文献

2
Pain Predicts Dropout From Substance Use Treatment.
J Stud Alcohol Drugs. 2024 May;85(3):381-388. doi: 10.15288/jsad.23-00099. Epub 2024 Jan 11.
3
Co-occurrence of chronic pain and anxiety/depression symptoms in U.S. adults: prevalence, functional impacts, and opportunities.
Pain. 2024 Mar 1;165(3):666-673. doi: 10.1097/j.pain.0000000000003056. Epub 2023 Sep 21.
5
Use of Medication for Opioid Use Disorder Among Adults With Past-Year Opioid Use Disorder in the US, 2021.
JAMA Netw Open. 2023 Aug 1;6(8):e2327488. doi: 10.1001/jamanetworkopen.2023.27488.
6
Cannabis use frequency and pain interference among people with HIV.
AIDS Care. 2023 Aug;35(8):1235-1242. doi: 10.1080/09540121.2023.2208321. Epub 2023 May 18.
7
Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022.
JAMA. 2023 Apr 25;329(16):1402-1404. doi: 10.1001/jama.2023.1207.
9
10
Racial and Ethnic Disparities in Buprenorphine Treatment Duration in the US.
JAMA Psychiatry. 2023 Jan 1;80(1):93-95. doi: 10.1001/jamapsychiatry.2022.3673.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验